RxDoctor Payments Data

Marla Jordan, MD

Neuromuscular Medicine · San German, PRNPI 1033303151

Payments from drug & device makers

$1,458in general payments, 2019–2025

Across 55 payments — averaging $26.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$241
  • Novartis$237
  • Eisai Inc.$129
  • UCB, Inc.$115
  • E.r. Squibb & Sons, L.L.C.$102
  • AstraZeneca$88
  • plus $546 from 10 others

What the payments were for

  • Food & beverage$1,44099%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$17,372
Medicare patients
32
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone20$280,513
Kesimpta PenOfatumumab23$207,590
RebifInterferon Beta-1a/Albumin15$156,262
Nurtec OdtRimegepant Sulfate87$138,734
NuplazidPimavanserin Tartrate24$123,535
Emgality PenGalcanezumab-Gnlm71$57,847
RytaryCarbidopa/Levodopa51$51,491
UbrelvyUbrogepant31$49,041
Emgality SyringeGalcanezumab-Gnlm45$36,529
Rivastigmine314$34,607
MestinonPyridostigmine Bromide12$32,611
Aimovig AutoinjectorErenumab-Aooe13$9,891
Memantine Hcl485$7,765
Pyridostigmine Bromide67$4,642
Memantine Hcl ErMemantine Hcl44$4,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$24$138,73487 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$75$56,609141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in San German

Where these figures come from

Is this you, or does something look wrong? →